Drug Trial Radar · NCT00433511
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
4,994
Actual
Start
Nov 2, 2007
Primary completion
Jan 7, 2014
Study completion Feb 20, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Feb 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, and paclitaxel to see how well they work with or without bevacizumab in treating patients with cancer that has spread to the lymph nodes (lymph node-positive) or cancer that has not spread to the lymph nodes but is at high risk for returning (high-risk, lymph node-negative breast cancer). Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery and help prevent the tumor from returning. It is not yet known whether doxorubicin hydrochloride, cyclophosphamide, and paclitaxel are more effective with or without bevacizumab.
Conditions
- Breast Adenocarcinoma
Interventions
BevacizumabBiological
Given IV
CyclophosphamideDrug
Given IV
Doxorubicin HydrochlorideDrug
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
PaclitaxelDrug
Given IV
Placebo AdministrationOther
Given IV
Quality-of-Life AssessmentOther
Ancillary studies (closed as of 5/28/10)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-free Survival (IDFS) Rate at 5 YearsTime frame: Assessed at 5 years
Locations
842 sites in 3 countries. Site status is shown where the registry gives one.
Northeast Alabama Regional Medical Center
Anniston, Alabama
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Providence Hospital
Mobile, Alabama
Alaska Regional Hospital
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Virginia G Piper Cancer Care-Del Camino
Scottsdale, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona
Mercy Hospital Fort Smith
Fort Smith, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
PCR Oncology
Arroyo Grande, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
East Bay Radiation Oncology Center
Castro Valley, California
Eden Hospital Medical Center
Castro Valley, California
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California
Bay Area Breast Surgeons Inc
Emeryville, California
Kaiser Permanente-Fremont
Fremont, California
Valley Medical Oncology Consultants-Fremont
Fremont, California
Washington Health
Fremont, California
California Cancer Associates for Research and Excellence (cCare)
Fresno, California
Glendale Memorial Hospital and Health Center
Glendale, California
Marin Cancer Care Inc
Greenbrae, California
Marin General Hospital
Greenbrae, California
UC San Diego Moores Cancer Center
La Jolla, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
Fremont - Rideout Cancer Center
Marysville, California
Community Hospital of Monterey Peninsula
Monterey, California
El Camino Hospital
Mountain View, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Sutter Cancer Research Consortium
Novato, California
Wilma Chan Highland Hospital
Oakland, California
Alta Bates Summit Medical Center - Summit Campus
Oakland, California
Bay Area Tumor Institute
Oakland, California
Hematology and Oncology Associates-Oakland
Oakland, California
Tom K Lee Inc
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Desert Regional Medical Center
Palm Springs, California
Showing 40 of 842 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.